Search
Bucetin
go.drugbank.com/drugs/DB13278ApprovedWithdrawnBucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]
Oteseconazole
go.drugbank.com/drugs/DB13055ApprovedInvestigational[A247050] The use of oteseconazole is contraindicated in females of reproductive potential due to its embryo-fetal toxicity risks.[L41635] This drug was approved by the FDA on April 26, 2022. … [L41635,A247020] By binding and inhibiting CYP51, oteseconazole is active against most microorganisms associated with recurrent vulvovaginal candidiasis (RVVC).
Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic UseBronopol
go.drugbank.com/drugs/DB13960ApprovedNevertheless, ongoing contemporary re-evaluations of bronopol use in large markets such as Canada now place various compositional and product restrictions on the use of the agent in cosmetic products [ … First synthesized in 1897, bronopol was primarily used as a preservative for pharmaceuticals and was registered in the United States in 1984 for use in industrial bactericides, slimicides and preservatives
Mixtures: Test Thin-Layer Rapid Use Patch TestPindolol
go.drugbank.com/drugs/DB00960ApprovedInvestigational[L32353] Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. … [A231059] Research into pindolol's use in the treatment of hypertension began in the early 1970s.[A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348]
Phenyl salicylate
go.drugbank.com/drugs/DB11071ApprovedIt is synthesized by heating salicylic acid with phenol [L2468], [MSDS]. Phenyl salicylate is used as a food additive in the USA [L2479]. … It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in [DB00945] ).
Mixtures: UtaImetelstat
go.drugbank.com/drugs/DB14909ApprovedInvestigational[A187838] Imetelstat received FDA approval in June 2024 for use in certain patients with MDS who have transfusion-dependent anemia and are unable to use ESAs.[L50883,L50888] … [A187838] Standard therapy for anemia in patients with MDS involves the use of erythropoiesis-stimulating agents (e.g.
Lobeglitazone
go.drugbank.com/drugs/DB09198InvestigationalLobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes. … Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019.
Nonoxynol-9
go.drugbank.com/drugs/DB06804ApprovedWithdrawnIt is the most commonly used spermicidal contraceptive in the UK and the USA. In several European countries, spermicides are no longer on the market. … N-9 has been in use for more than 30 years as an over-the-counter (OTC) drug in creams, gels, foams and condom lubricants.
Categories: Hormonal Contraceptives for Systemic UseMaribavir
go.drugbank.com/drugs/DB06234ApprovedInvestigationalas [ganciclovir] or [foscarnet], target CMV DNA polymerase - while generally effective, these medications tend to promote the development of CMV resistance to DNA polymerase-based therapies, and their use … [L39327] The drug was also approved by Health Canada in September 2022 [L43262] and by European Commission in November 2022.[L44411]
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseBelantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide … In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program.